Skip to main content

Peer Review reports

From: Sintilimab plus bevacizumab and CapeOx (BBCAPX) on first-line treatment in patients with RAS mutant, microsatellite stable, metastatic colorectal cancer: study protocol of a randomized, open-label, multicentric study

Original Submission
7 Mar 2023 Submitted Original manuscript
29 Mar 2023 Author responded Author comments - Ying Yuan
Resubmission - Version 2
29 Mar 2023 Submitted Manuscript version 2
31 Mar 2023 Author responded Author comments - Ying Yuan
Resubmission - Version 3
31 Mar 2023 Submitted Manuscript version 3
15 May 2023 Reviewed Reviewer Report
7 Jun 2023 Reviewed Reviewer Report
22 Jun 2023 Author responded Author comments - Ying Yuan
Resubmission - Version 4
22 Jun 2023 Submitted Manuscript version 4
30 Jun 2023 Reviewed Reviewer Report
30 Jun 2023 Reviewed Reviewer Report
Resubmission - Version 5
Submitted Manuscript version 5
Publishing
30 Jun 2023 Editorially accepted
18 Jul 2023 Article published 10.1186/s12885-023-11139-z

You can find further information about peer review here.

Back to article page